Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-02847 on behalf of shareholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) who have been harmed by Progenics’ and its board of directors’ (the “Board”) alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with the proposed merger of the Company with Lantheus Holdings, Inc. (the “Proposed Transaction”).
On February 20, 2020, the Board caused the Company to enter into an agreement and plan of merger under which Progenics shareholders stand to receive 0.31 of a share of Lantheus Holdings, Inc. common stock for each share of Progenics stock they own.
The complaint alleges that the Form S-4 Registration Statement filed with the Securities and Exchange Commission violates Sections 14(a) and 20(a) of the Exchange Act because it provides materially incomplete and misleading information about the Company and the Proposed Transaction, including information concerning the Company’s financial projections and analysis, on which the Board relied to recommend the Proposed Transaction as fair to Progenics shareholders.
If you wish to serve as lead plaintiff, you must move the Court no later June 22, 2020. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you wish to obtain information concerning this action, you can do so by filing out the form below.
Progenics Pharmaceuticals, Inc. (PGNX)
* The submission of this form does not create an attorney-client relationship.
Filed on 04/23/2020
Court Southern District of New York
Lead Plaintiff Deadline 06/22/2020
24 days remaining
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
James M. Wilson, Jr. email@example.com Phone (212) 983-9330 Fax (212) 983-9331